Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 07/29 10:00:43 pm
44.75 USD   +0.67%
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/28 THURSDAY 7/28 I : Abt, ancx
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/28 ABBOTT LABORATORIES : Trademark Application for "CELL-DYN RUBY" Filed by Abbott ..
07/28 ABBOTT LABORATORIES : Federal Contracts Awarded by Federal Agencies in Iowa (Jul..
07/28 ABBOTT LABORATORIES : Trademark Application for "GERMIGUARD" Filed by Abbott Lab..
07/28 THURSDAY 7/28 INSIDER BUYING REPORT : Abt, ancx
07/28 DGAP-DD : Abbott Laboratories english
07/28 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
07/28DJALERE : Faces Criminal Probe Over Billing -- WSJ
07/28 ABBOTT LABORATORIES : has more reason to walk away from Alere deal
More news
Sector news : Pharmaceuticals - NEC
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/29 3 Free Options
07/29 Oracle's Larry Ellison Wants To Own It All - Starting With NetSuite (Podcast)
07/28 Alere Stock Goes Nuts, Abbott Likely Still Picking Up The Tab
07/28 Larry Ellison Conquers The World, Starting With NetSuite
07/28 INSIDERINSIGHTS.COM DAILY ROUND UP 7 : Blackrock Debt Strategies Fund, Bank Of C..
Advertisement
Financials ($)
Sales 2016 20 942 M
EBIT 2016 4 080 M
Net income 2016 2 323 M
Debt 2016 2 655 M
Yield 2016 2,32%
P/E ratio 2016 24,98
P/E ratio 2017 19,48
EV / Sales 2016 3,27x
EV / Sales 2017 3,11x
Capitalization 65 745 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 47,8 $
Spread / Average Target 6,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-0.36%65 745
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results